Cereno Scientific has issued the fourth tranche

The board of directors of Cereno Scientific AB (publ) (“Cereno”) has issued the fourth tranche of convertible bonds with warrants attached, amounting to SEK 3,500,000, to European High Growth Opportunities Securitization Fund, in accordance with the financing solution announced by Cereno through a press release on 19 March 2018.

The convertible bonds are issued at a price corresponding to 100 percent of the nominal value, which means that Cereno will be provided with SEK 3,500,000. Conversion of the convertible bonds may be requested, in full or in part, by the convertible holder during the twelve months period immediately following registration of the convertible bonds by the Swedish Companies Registration Office. The conversion price amounts to 93 percent of the lowest daily VWAP according to the Spotlight Stock Market’s market official price list for the share of class B in the Company during the fifteen (15) trading days preceding the day for the demand for conversion.

The convertible bonds are issued with 159,091 warrants attached, that entitle European High Growth Opportunities Securitization Fund to subscribe for additional 159,091 ordinary shares of series B within five years, at a subscription price of SEK 6,6 per share. The warrants are issued free of charge. At full exercise of the warrants, Cereno will be provided with approximately SEK 1,050,000 corresponding to 30 percent of the nominal amount of the convertible bonds.

The board’s issue resolutions have been made based on the authorization from the shareholders’ meeting on 13 June 2018.

For more information, please contact:
Sten R. Sörensen – CEO

Tel: +46 73 374 03 74
E-mail sten.sorensen@cerenoscientific.com

About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is a controlled release formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B, ISIN SE0008241558.

This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made available publically by the Company’s contact person on 18 July 2018.


Documents & Links